title: Basophil activation test with indomethacin to assess hypersensitivity to non-steroidal anti-inflammatory drugs: a preliminary study.
abstract: BACKGROUND
  The basophil activation test has been investigated for diagnosing hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs). This has not yet been done in relation to indomethacin.
  
  
  OBJECTIVE
  First seek to establish the viable concentrations of indomethacin and the diluent propylene glycol (PPG) in relation to basophils then test this in patients with hypersensitivity to NSAIDs.
  
  
  METHODS
  The ideal concentrations of PPG and indomethacin were assessed by incubating them with basophils from an atopic donor and evaluating the intensity of expression of CD63 molecules by means of flow cytometry. We also evaluated the cell viability directly using the trypan blue in seven controls. Then indomethacin was tested in ten patients with hypersensitivity to NSAIDs compared with eight persons in control group.
  
  
  RESULTS
  In relation to the toxicity of propylene glycol, concentrations less than or equal to 0.5% are safe. There was no cytotoxicity or nonspecific stimulation from using indomethacin at concentrations of 10 mcg/mL, 1 mcg/mL and 0.1 mcg/mL. Then indomethacin was tested at concentration of 10 mcg/mL diluted in 0.5% propylene glycol in both groups. There was no statistical difference in the intensity of activation of basophils comparing the group of patients with hypersensitivity to NSAIDs and the control group.
  
  
  CONCLUSIONS
  As a diluent for indomethacin, PPG should be used at concentrations less than or equal to 0.5%. The indomethacin at concentration of 10 mcg/mL was not able to differentiate patients with and without hypersensitivity to NSAIDs.
authors.affiliation: Division of Allergy and Clinical Immunology of Marilia Medical School (FAMEMA), Av. Vicente Ferreira, 648, Marilia, São Paulo, Brazil. calamita@unimedmarilia.com.br
authors.forename: Zamir
authors.initials: Z
authors.lastname: Calamita
authors.forename: Roseli Nunes
authors.initials: RN
authors.lastname: da Silveira Antunes
authors.forename: Andrea Bronhara
authors.initials: AB
authors.lastname: Pelá Calamita
authors.forename: Wilson Baleotti
authors.initials: WB
authors.lastname: Júnior
authors.forename: Débora
authors.initials: D
authors.lastname: de Aguiar Cavaretto
authors.forename: Josianne Thomazini
authors.initials: JT
authors.lastname: Fukazawa
authors.forename: Odilon Marques
authors.initials: OM
authors.lastname: de Almeida Filho
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000276:immunology; D001491:Basophils / Q000187:drug effects* / Q000276:immunology; D002470:Cell Survival / Q000187:drug effects / Q000276:immunology; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000276:immunology; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012882:Skin Tests / Q000379:methods*; D060149:Tetraspanin 30 / Q000276:immunology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D060149:Tetraspanin 30; D007213:Indomethacin